Acrivon Therapeutics, Inc. (ACRV) Tops Q1 EPS by 50c

Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q1 EPS of ($0.51), $0.50 better than the analyst estimate of ($1.01).

For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.

You May Also Be Interested In

• Warsh: Inflation Data Don’t Suggest Trend Meaningfully Improved
• Macy's (M) Declares $0.1915 Quarterly Dividend; 3.4% Yield
• Baird on AECOM Technology (ACM): 'Underlying design demand, International margins, and market share gains remain good'